-+ 0.00%
-+ 0.00%
-+ 0.00%

External Safety Review Committee Recommended Pasithea Therapeutics' Phase 1/1b Study To Assess PAS-004 For Neurofibromatosis Type 1 To Proceed To Cohort 2, 8mg Tablet, Without Modification, Initial Interim Data From First Two Cohorts Expected In Q1 2026

Benzinga·09/08/2025 11:08:07
Listen to the news
  • Recommendation that trial escalate to next dose level of 8mg tablet --
  • Initial interim clinical data from first two cohorts expected in Q1 2026